FDA clearance and a powerful new patent keeps this robotics company in the limelight
By Casey Nobile
January 25, 2013
A number of analysts were disappointed that the iRobot booth lacked a groundbreaking new product release at CES 2013. Instead, the company boasted upgrades to its consumer products, which now make up about 76 percent of annual revenues. (The gross margin on those bots is superior to those sold by its defense segment.)
News this week, however, sees the company step firmly into the healthcare market with a new patent indicating that the 3-D printing industry is next on the list.
Shares experienced a healthy spike Thursday when the iRobot’s RP-VITA…
This is a preview article. Please register to view the entire article.